Terra Alpha Investments LLC Takes $1.24 Million Position in IDEXX Laboratories, Inc. $IDXX

Terra Alpha Investments LLC acquired a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 1,835 shares of the company’s stock, valued at approximately $1,241,000. IDEXX Laboratories comprises about 1.3% of Terra Alpha Investments LLC’s holdings, making the stock its 27th biggest holding.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its stake in shares of IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock valued at $397,000 after buying an additional 15 shares during the last quarter. CWA Asset Management Group LLC grew its stake in shares of IDEXX Laboratories by 3.5% during the fourth quarter. CWA Asset Management Group LLC now owns 509 shares of the company’s stock valued at $344,000 after buying an additional 17 shares during the last quarter. Stratos Wealth Partners LTD. grew its stake in shares of IDEXX Laboratories by 1.7% during the third quarter. Stratos Wealth Partners LTD. now owns 1,069 shares of the company’s stock valued at $683,000 after buying an additional 18 shares during the last quarter. Cary Street Partners Investment Advisory LLC grew its stake in shares of IDEXX Laboratories by 11.5% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 174 shares of the company’s stock valued at $111,000 after buying an additional 18 shares during the last quarter. Finally, Rockland Trust Co. boosted its holdings in shares of IDEXX Laboratories by 4.4% during the fourth quarter. Rockland Trust Co. now owns 425 shares of the company’s stock worth $288,000 after purchasing an additional 18 shares during the period. 87.84% of the stock is owned by institutional investors.

IDEXX Laboratories Stock Down 0.8%

Shares of IDEXX Laboratories stock opened at $528.79 on Friday. The company has a current ratio of 1.12, a quick ratio of 0.82 and a debt-to-equity ratio of 0.19. IDEXX Laboratories, Inc. has a 12-month low of $496.61 and a 12-month high of $769.98. The company’s fifty day simple moving average is $572.08 and its two-hundred day simple moving average is $645.56. The company has a market cap of $41.71 billion, a P/E ratio of 38.94, a PEG ratio of 3.10 and a beta of 1.58.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, beating the consensus estimate of $3.41 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The business’s revenue was up 14.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.91 EPS. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. Research analysts anticipate that IDEXX Laboratories, Inc. will post 14.68 EPS for the current year.

Analyst Upgrades and Downgrades

IDXX has been the subject of a number of analyst reports. Piper Sandler dropped their target price on shares of IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a report on Monday, February 9th. BTIG Research dropped their target price on shares of IDEXX Laboratories from $830.00 to $800.00 and set a “buy” rating for the company in a report on Tuesday, February 3rd. UBS Group dropped their target price on shares of IDEXX Laboratories from $730.00 to $640.00 and set a “neutral” rating for the company in a report on Tuesday, April 28th. Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday. Seven analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $751.00.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the sale, the chief executive officer directly owned 83,606 shares of the company’s stock, valued at approximately $54,975,125.30. The trade was a 21.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $628.62, for a total value of $920,299.68. Following the sale, the director directly owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 34,612 shares of company stock valued at $22,525,070. Insiders own 0.79% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.